Efficacy and safety of bosentan-related therapy in neonates with persistent pulmonary hypertension of the newborn: a systematic review and meta-analysis.

Front Pediatr · 2026 · PMC13272431 · PMID 42317665

Europe PMC DOI

hedged sentences

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

of borderline significanceP = 0.05actually significant

Reduction in pulmonary artery pressure also favoured bosentan-related therapy, although the difference was of borderline significance (MD: −2.69, 95% CI −5.40–0.01; P = 0.05).

also in 2,624 other papers

showed a trendno p-value reported

The pooled analysis showed a trend toward a shorter length of hospital stay in the bosentan-related treatment group than in the control group, but the difference was not statistically significant (MD = −1.06, 95% CI: −2.38 to 0.27, P = 0.12).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.